期刊文献+

含呋喃唑酮短程三联及四联药物治疗幽门螺杆菌感染成本效果分析 被引量:2

Chinical cost-effectiveness analysis on eradication of H.Pylori using regiment of one-week quadruple and triple therapy
下载PDF
导出
摘要 Aim To evaluate the efficacy and cost-effectiveness of one-week regiment of quadruple and triple therapy containing:Lansoprazle(L),colloidal bismuth subciteate(B),amoxicillin(A),metrnidozole(M) and furazolidone(F).Methods 227 patients with duodenal ulcer(DU) or non-ulcer dyspepsia (NUD) confirmed by endoscopy were received LAFB,LAM or LAF,twice daily for 7 days.Endoscopy was performed in DU and 14 C-UBT was performed in NUD 4 weeks after completion of treatment.Results (1)The eradication rate of H.pylori by LAFB,LAM and LAF were 96.30%,84.51% and 70.59% respectively(LAFB vs LAF and LAF,P<0.05;LAFB vs LAM P<0.01).The healing rate of DU had no difference between three regiment P<0.05).The cost-effectiveness analysis on eradication of H.pylori showed that cost/effectiveness (C/E) of LAFB is the lowest.(2)The healing rate of DU ulcer in H.pylori eradicated patients was higher than that in uneradicated ones(98.94% vs 50%,P<0.01).The rate of ulcer recurrent of year was lower in H.pylori eradicated patients than that in uneradicated patients(2.15% vs 71.42%,P<0.01).(3)The rate of relieving symptom and recurrenting symptom in one year had no difference between H.pylori eradicated patients and uneradicated patiens in NUD(71.74% vs 70% and 53.03 vs 50,P>0.05).Conclusions The efficacy of one week regiment of quadruple therapy is higher than that in triple therapy but the side effect was not higher.The higher eradication rate is caused by combination of furazolidone,bacause it is low resis tant to H.pylori.It is also a cost-saving strategy.Eradication of H.pylori infection could improve ulcer healing and decrease the rate of ulcer recurrent but is not likely to relieve symptomes in NUD patients. Aim To evaluate the efficacy and cost-effectiveness of one-week regiment of quadruple and triple therapy containing:Lansoprazle(L),colloidal bismuth subciteate(B),amoxicillin(A),metrnidozole(M) and furazolidone(F).Methods 227 patients with duodenal ulcer(DU) or non-ulcer dyspepsia (NUD) confirmed by endoscopy were received LAFB,LAM or LAF,twice daily for 7 days.Endoscopy was performed in DU and 14 C-UBT was performed in NUD 4 weeks after completion of treatment.Results (1)The eradication rate of H.pylori by LAFB,LAM and LAF were 96.30%,84.51% and 70.59% respectively(LAFB vs LAF and LAF,P<0.05;LAFB vs LAM P<0.01).The healing rate of DU had no difference between three regiment P<0.05).The cost-effectiveness analysis on eradication of H.pylori showed that cost/effectiveness (C/E) of LAFB is the lowest.(2)The healing rate of DU ulcer in H.pylori eradicated patients was higher than that in uneradicated ones(98.94% vs 50%,P<0.01).The rate of ulcer recurrent of year was lower in H.pylori eradicated patients than that in uneradicated patients(2.15% vs 71.42%,P<0.01).(3)The rate of relieving symptom and recurrenting symptom in one year had no difference between H.pylori eradicated patients and uneradicated patiens in NUD(71.74% vs 70% and 53.03 vs 50,P>0.05).Conclusions The efficacy of one week regiment of quadruple therapy is higher than that in triple therapy but the side effect was not higher.The higher eradication rate is caused by combination of furazolidone,bacause it is low resis tant to H.pylori.It is also a cost-saving strategy.Eradication of H.pylori infection could improve ulcer healing and decrease the rate of ulcer recurrent but is not likely to relieve symptomes in NUD patients.
出处 《胃肠病学和肝病学杂志》 CAS 2002年第3期272-275,277,共5页 Chinese Journal of Gastroenterology and Hepatology
关键词 幽门螺杆菌感染 药物疗法 呋喃唑酮 药物疗法 治疗 Helicobacter pylori Drug therapy Furazolidone Cost-effectiveness analysis
  • 相关文献

参考文献2

二级参考文献11

  • 1刘文忠 徐蔚文.幽门螺杆菌对甲硝唑及克拉霉素耐药率的变迁[A]..中华医学会第六次全国消化病学术会议论文摘要[C].西安,1999,10..
  • 2XiaoSD,LiuWZ,HuPJ,XiaDH,TytgatGNJ.HighcurerateofHelicobacterpyloriinfectionus-ingtripotassiumdicitratobismuthate,furazoli-doneandclarithromycintripletherapyfor1week.AlimentPharmacolTher,1999,13:311~315.
  • 3LiuWZ,XiaoSD,ShiY,WuSM,ZhangDZ,XuWW,TytgatGNJ.Furazolidone-containingshort-termtripletherapiesareeffectiveinthetreat-mentofHelicobacterpyloriinfection.AlimentPharmacolTher,1999,13:317~322.
  • 4LindT,MegraudF,UngeP,BayerdorfferE,O'morainC,SpillerR,VeldhuyzenVanZantenS,BardhanKD,HellblomM,WrangstadhM,ZeijlonL,CederbergC.TheMACH2study:roleofome-prazoleineradicationofHelicobacterpyloriwith1-weektripletherapies[seecomments].Gastroen-terology,1999,116:248~253.
  • 5vanderHulstRWM,KellerJJ,RauwsEA,TytgatGNJ.TreatmentofHelicobacterpyloriinfection:areviewoftheworldliterature.Helicobacter,1996,1:6~19.
  • 6WalshJH,PetersonWL.ThetreatmentofHelico-bacterpyloriinfectioninthemanagementofpep-ticulcerdisease[seecomments].NEnglJMed,1995,333:984~991.
  • 7BazzoliF,ZagariM,PozzatoP,VaroliO,FossiS,RicciardielloL,AlampiG,NicoliniG,SottiliS,SimoniP,RodaA,RodaE.Evaluationofshort-termlow-dosetripletherapyforeradicationofHe-licobacterpyloribyfactorialdesigninarado-mized,double-blindcontrolledstudy.AlimentPharmacolTher,1998,12:439~445.
  • 8LingTKW,ChengAFB,SungJJY,YiuPY,ChungSS.AnincreaseinHelicobacterpyloristrainsresistanttometronidazole:Afive-yearstudy.Helicobacter,1996,1:57~61.
  • 9XiaoSD,LiuWZ,XiaDH,JiangSJ,WangRN,ZhangZH,XuWW.TheefficacyoffurazolidoneandmetronidazoleinthetreatmentofchronicgastritisassociatedwithHelicobacter(Campylobacter)pylori-arandomizeddouble-blindplacebo-controlledclinictrial.Hepatogastroenterology,1990,37:503~506.
  • 10MisiewiczJJ.TheSydneysystem:anewclassificationofgastritis.JGastroenterolHepatol,1991,6:207~208.

共引文献45

同被引文献25

  • 1张发云,杨真威,李国明,梁伟.幽门螺杆菌与2005年诺贝尔医学奖[J].生物化学与生物物理进展,2005,32(11):1016-1019. 被引量:16
  • 2P Malfertheiner,F Megraud,C O'Morain,F Bazzoli,E El-Omar,D Graham,R Hunt,T Rokkas,N Vakil,EJ Kuipers,朱琦.幽门螺杆菌感染处理的当前观念——MaastrichtⅢ共识报告[J].胃肠病学,2007,12(3):159-169. 被引量:15
  • 3毛增贵.奥美拉唑、枸橼酸铋钾、呋喃唑酮、阿莫西林联合治疗Hp阳性的消化性溃疡的临床研究[J].国际医药卫生导报,2007,13(10):64-66. 被引量:8
  • 4Suerbaum S,Michetti P. Helicobacter pylori infection [ J]. N Engl J Med,2002,347 ( 15 ) : 1175-1186.
  • 5Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection : the Maastricht III Consensus Report [J]. Gut,2007,56(6) :772-781.
  • 6Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing [ J]. Gut,2004,53 (9) :1374-1384.
  • 7Cheon JH, Kim N, Lee DH, et al. Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection [ J]. Korean J Gastroenterol,2005,45 (2) :111-117.
  • 8Treiber G, Amman S, Malfertheiner P, et al. Impact of furazolidone- based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures [ J]. Helicobacter, 2002,7 ( 4 ) : 225- 231.
  • 9Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy [ J ]. Helicobacter, 2007,12 ( 4 ) : 275- 278.
  • 10Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection [J]. Aliment Pharmacol Ther,2003,17( 11 ) :1333-1343.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部